Allergy Therapeutics: revenue growth and clinical update

25th September 2019

Allergy Therapeutics plc has announced year end results, in which the company continued to grow market share in Europe with its portfolio of allergy vaccines. In the TV clip below, the management outlines where the growth has been and also the progress made with its peanut allergy vaccine, which is due to start a Phase I trial next year.

Allergy Therapeutics, Video for investors

Investor Meetings

Five Minute Pitch TV is run by FMP-IR Ltd, who organise investor roadshows for Allergy Therapeutics. Any professional investors wishing to meet the management  can contact us below:

Nicholas Peters, Head of Investor Relations
Mobile: +44 (0)7909 972 080
E-mail: nickp@fmp-ir.co.uk

James Mcilwraith, Head of TV
Mobile: +44 (0)7702 197 899
E-mail: jamesm@fmp-ir.co.uk

 

Allergy Therapeutics Investors Video

CEO Manuel Llobet on Five Minute pitch TV updating investors on the progress of their allergy vaccines

Click here to view Allergy Therapeutics investor video